The role of statins in chronic heart failure

Current Opinion in Cardiology

Volumn 24, Issue 2, 2009, Pages 167-171

  Sadek, Mouhannad M ^a   Haddad, Taleen ^a   Haddad, Haissam ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

Heart failure; Statins; Survival

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; LOW DENSITY LIPOPROTEIN; PLACEBO; ROSUVASTATIN;

CARDIOMYOPATHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INFECTION; INFLAMMATION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; MUSCLE DISEASE; MYOPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHABDOMYOLYSIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES;

EID: 62249202840     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e3283229afb     Document Type: Review

References (29)

1. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics - 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007; 115: e69-e171.
2. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adultr a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112:e154-e235.
3. Raina A, Pickering T, Shimbo D. Statin use in heart failure: a cause for concern? Am Heart J 2006; 152:39-49.
4. Ramasubbu K, Estep J, White DL, et al. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol 2008; 51:415-426. This review examines the potential benefits of statins in patients with heart failure.
5. Fonarow GC. Randomized clinical outcome trials of statins in heart failure. Heart Fail Clin 2008; 4:225-229. This study reviews the randomized clinical trials of statins in heart failure with special focus on CORONA.
6. van der Harst P, Wagenaar LJ, Buikema H, et al. Effect of intensive versus moderate lipid lowering on endothelial function and vascular responsiveness to angiotensin II in stable coronary artery disease. Am J Cardiol 2005; 96:1361-1364.
7. Nickenig G, Baumer AT, Temur Y, et al. Stalin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999; 100:2131-2134.
8. Kjekshus J, Pedersen TR, Olsson AG, et al. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 1997; 3:249-254.
9. Hanna IR, Heeke B, Bush H, et al. Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm 2006; 3:881-886.
10. Vyas AK, Quo H, Moss AJ, et al. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 2006; 47:769-773.
11. Sandek A, Bauditz J, Swidsinski A, et al. Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol 2007; 50:1561-1569.
12. Rauchhaus M, Coats AJ, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet 2000; 356:930-933.
13. Sander S, Coleman Cl, Patel AA, et al. The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. J Card Fail 2006; 12:464-472.
14. Moosmann B, BeN C. Selenoprotein synthesis and side-effects of statins. Lancet 2004; 363:892-894.
15. Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated with improved survival in ischemic and nonischemic heart failure. J Am Coll Cardiol 2004; 43:642-648.
16. Ray JG, Gong Y, Sykora K, Tu JV. Statin use and survival outcomes in elderly patients with heart failure. Arch Intern Med 2005; 165: 62-67.
17. Krum H, Bailey M, Meyer W, et al. Impact of statin therapy on clinical outcomes in chronic heart failure patients according to beta-blocker use: results of CIBIS II. Cardiology 2007; 108:28-34. This substudy from Cardiac Insufficiency Bisoprolol study (CIBIS) II addresses the effects of statins on the heart failure population who are on β-blockers.
18. Krum H, Latini R, Maggioni AP, et al. Statins and symptomatic chronic systolic heart failure: a posthoc analysis of 5010 patients enrolled in Val-HeFT. Int J Cardiol 2007; 119:48-53.
19. Foody JM, Shah R, Galusha D, et al. Statins and mortality among elderly patients hospitalized with heart failure. Circulation 2006; 113:1086-1092.
20. Anker SD, Clark AL, Winkler R, et al. Statin use and survival in patients with chronic heart failure - results from two observational studies with 5200 patients. Int J Cardiol 2006; 112:234-242.
21. Mozaffarian D, Nye R, Levy WC. Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol 2004; 93:1124-1129.
22. Go AS, Lee WY, Yang J, et al. Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA 2006; 296:2105-2111.
23. Folkeringa RJ, Van Kraaij DJ, Tieleman RG, et al. Statins associated with reduced mortality in patients admitted for congestive heart failure. J Card Fail 2006; 12:134-138.
24. Dickinson MG, Ip JH, Olshansky B, et al. Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Am Heart J 2007; 153:573-578.
25. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357:2248-2261. In this study, rosuvastatin did not reduce the primary outcome or the number of deaths from any cause in older patients with heart failure.
26. GISSI-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372:1231-1239. This study showed that rosuvastatin is safe in patients with chronic heart failure but did not affect clinical outcomes.
27. Vasan RS, Sullivan LM, Roubenoff R, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 2003; 107:1486-1491.
28. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-2207. In this study, rosuvastatin reduced the incidence of major cardiovascular events in patients with normal lipids but hsCRP.
29. Endres M, Laufs U. Discontinuation of statin treatment in stroke patients. Stroke 2006; 37:2640-2643.